| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2023-12-21T06:43:27Z |
|
| dc.date.available |
2023-12-21T06:43:27Z |
|
| dc.date.issued |
2019-10 |
|
| dc.identifier.uri |
https://www.sciencedirect.com/science/article/abs/pii/S1734114019301185 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13482 |
|
| dc.description.abstract |
Neprilysin inhibitors (NEPi) are assisting the renin-angiotensin system (RAS) inhibitors in halting diabetic cardiomyopathy (DCM). Away from conventional tactic, a recent report revealed the renoprotective potential of NEPi and angiotensin-converting enzyme (ACE2) activator combination therapy against diabetic nephropathy. However, this combination so far not evaluated against DCM, thus the present investigation aiming the same. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Cardiomyopathy |
en_US |
| dc.subject |
Neprilysin inhibitors (NEPi) |
en_US |
| dc.subject |
Angiotensin-converting enzyme (ACE2) |
en_US |
| dc.title |
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy |
en_US |
| dc.type |
Article |
en_US |